"Something is wrong in the ras kingdom" - evidence for the involvement of p21Ras/MAP kinase in autoimmune diseases

Current Rheumatology Reviews

Volumn 7, Issue 4, 2011, Pages 301-305

  Rapoport, M J ^a   Bloch, O ^b   Amit Vazina, M ^c  

^a Department C of Internal Medicine ^*  (Israel)

^b Laboratory of Diabetes and Autoimmunity   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Autoimmune diseases; P21Ras MAPK pathway

Indexed keywords

IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE; P21 ACTIVATED KINASE; RAS PROTEIN; ROQUINIMEX; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; AUTOIMMUNE DIABETES; AUTOIMMUNE DISEASE; AUTOIMMUNE INSULITIS; B LYMPHOCYTE; BASOPHIL; CELIAC DISEASE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELL SELECTION; CHRONIC IDIOPATHIC URTICARIA; CLINICAL FEATURE; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE SEVERITY; ENTERITIS; ENZYME ACTIVITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; INTRACELLULAR SIGNALING; LYMPHOCYTE; MAST CELL; METABOLIC REGULATION; MULTIPLE SCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; URTICARIA;

EID: 82155192966     PISSN: 15733971     EISSN: 18756360     Source Type: Journal    
DOI: 10.2174/157339711798221059     Document Type: Review

References (61)

1. Buday L, Egan SE, Rodriguez V P, Cantrell DA, Downward J. A complex of Grb2 adaptor protein, Sos exchange factor, and a 36- kDa membrane-bound tyrosine phosphoprotein is implicated in ras activation in T cells. J Biol Chem 1994; 269: 9019-23.
2. Ebinu JO, Bottorff DA, Chan EY, Stang SL, Dunn RJ, Stone JC. RasGRP, a Ras guanil nucleotide-releasing protein with calcium- and diacylglycerol-binding motifs. Science 1998; 280: 1082-6.
3. Dower NA, Stang SL, Bottorff DA, et al. RasGRP is essential for mouse thymocyte differentiation and TCR signaling. Nat Immunol 2000; 1: 317-21.
4. Geyer M, Wittinghofer A. GEFs, GAPs, GDIs and effectors: taking a closer (3D) look at the regulation of Ras-related GTP-binding proteins. Curr Opin Struct Biol 1997; 7: 786-92.
5. Bivona TG, Perez De Castro I, Ahearn IM, et al. Phospholipase Cgamma activates Ras on the Goldgi apparatus by means of RasGRP1. Nature 2003; 424: 694-8.
6. Mor A, Gampi G, Du G, et al. The lymphocyte function-associated antigen- 1 receptor costimulates plasma membrane Ras via phospholipase D2. Nat Cell Biol 2007; 9: 713-9.
7. Chiu VK, Bivona T, Hach A, et al. Ras signalling on the endoplasmic reticulum and the Golgi. Nat Cell Biol 2002; 4: 343-50.
8. Caloca M J, Zugaza J L, Bustelo X R. Exchange factors of the RasGRP family mediate Ras activation in the Golgi. J Biol Chem 2003; 278: 33465-73.
9. Roose J P, Mollenauer M, Ho M, Kurosaki T, Weiss A. Unusual interplay of two types of Ras activators, RasGRP and SOS, establishes sensitive and robust Ras activation in lymphocytes. Mol Cell Biol 2007; 27(7): 2732-45.
10. Downward J, Graves JD, Warne PH, Rayter S, Cantrell DA. Stimulation of p21ras upon T-cell activation. Nature 1990; 346: 719-23.
11. Daniels MA, Teixeiro E, Gill J, et al. Thymic selection threshold defined by compartmentalization of Ras/MAPK signaling. Nature 2006; 444: 724-29.
12. RAS activation. J Exp Med 1993; 177: 1221-26.
13. Salojin K, Zhang J, Cameron M, et al. Impaired plasma membrane targeting of Grb2-murine Son of Sevenless (mSOS) complex and differential activation of the Fyn-T Cell Receptor (TCR)-z-Cbl pathway mediate T cell hyporesponsiveness in autoimmune nonobese diabetic mice. J Exp Med 1997; 186: 887-97.
14. Slavin S, Weiss L, Wenlang X, Gross DJ. Successful treatment of diabetes in NOD mice with advanced disease by islet isografts following immunoregulation with Linomide (quinoline-3- carboxamide). Cell Transplant 1996; 5: 627-30.
15. Slavin S, Sidi H, Weiss L, Rosenman E, Kalland T, Gross D. Linomide a new treatment for autoimmune diseases: the potential in type I diabetes. Diabetes Metab Rev 1993; 9: 311-15.
16. Gross DI, Sidi CH, Weiss L, Kalland T, Rosenman E, Slavin S. Prevention of diabetes mellitus in non obese diabetic mice by linomide: a novel immunomodulator drug. Diabetologia 1994; 37: 1195-201.
17. Larson ET. The mechanisms of action of the new immunomodulator LS26 I6 on T cell responses. Int J Immunopharmacol 1987; 9: 425.
18. Rapoport MJ, Weiss L, Mor A, Bistritzer T, Ramot Y, Slavin S. Prevention of autoimmune diabetes by linomide in nonobese diabetic (NOD) mice is associated with up-regulation of the TCR- mediated activation of p21(ras). J Immunol 1996; 157: 4721-5.
19. Rapoport MJ, Mor A, Vardi P, Ramot Y, Levi O, Bistritzer T. Defective activation of p21ras in peripheral blood mononuclear cells from patients with insulin dependent diabetes mellitus. Autoimmunity 1999; 29(2): 147-54.
20. Rapoport M J, Levi O, Buchs A, et al. High insulin requirements and poor metabolic control do not modify the expression, regulation and PKC mediated activation of the p21ras pathway in PBMC from Type II Diabetic patients. International Journal of Experimental Diabetes Research 2001; 2: 47-54.
21. Qu HQ, Grant SFA, Bradfield JP, et al. Association of RasGRP1 with type 1 diabetes is revealed by combined follow-up of two genome-wide studies. J Med Genet 2009; 46: 553-4.
22. Mok CC, Lau CS. Pathogenesis of system lupus erythematosus. J Clin Pathol 2003; 56: 481-90.
23. Crispin JC, Kyttaris VC, Juang Y-T, Tsokos GC. How signaling and gene transcription aberrations dictate the systemic lupus erythematosus T cell phenotype. Trends in Immunology 2008; 29(3): 110-15.
24. Mor A, Philips MR, Pillinger MH. The role of Ras signaling in lupus T lymphocytes: Biology and pathogenesis. Clinical Immunology 2007; 125: 215-23.
25. Rapoport MJ, Mor A, Amit M, et al. Decreased expression of the p21ras stimulatory factor hSOS in PBMC from inactive SLE patients. Lupus 1999; 8: 24-8.
26. Rapoport MJ, Amit M, Aharoni D, et al. Constitutive up-regulated activity of MAP kinase is associated with down-regulated early p21Ras pathway in lymphocytes of SLE patients. J Autoimmun 2002; 9: 63-70.
27. Rapoport MJ, Sharabi A, Aharoni D, et al. Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a downregulation of apoptosis and of the pro-apoptotic factor JNK kinase. Clin Immunol 2005; 117: 262-70.
28. Portales-Pérez D, González-Amaro R, Abud-Mendoza C, Sánchez-Armáss S. Abnormalities in CD69 expression, cytosolic pH and Ca2+ during activation of lymphocytes from patients with systemic lupus erythematosus. Lupus 1997; 6(1): 48-56.
29. Su CC, Shau WY, Wang CR, Chuang CY, Chen CY. CD69 to CD3 ratio of peripheral blood mononuclear cells as a marker to monitor systemic erythematosus disease activity. Lupus 1997; 6(5): 449-54.
30. Cedeno S, Cifarelli DF, Blasini AM, et al. Defective activity of ERK-1 and ERK-2 mitogen-activated protein kinases in peripheral blood T lymphocytes from patients with systemic lupus erythematosus: potential role of altered coupling Ras guanine nucleotide exchange factor hSos to adapter protein Grb2 in lupus T cells. Clin Immunol 2003; 106: 41-9.
31. Deng C, Lu Q, Zhang Z, et al. Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum 2003; 48: 746-56.
32. Yasuda S, Stevens RL, Terada T et al. Defective expression of Ras Guanyl Nucleotide-Releasing Protein 1 in a subset of patients with systemic lupus erythematosus. J Immunol 200; 179: 4890-900.
33. Molad Y, Amit-Vasina M, Bloch O, Yona E, Rapoport M.J. Increased ERK and JNK activities correlate with disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2010; 69: 175-80.
34. Greaves M. Chronic urticaria. J Allergy Clin Immunol 2000; 105: 664-72.
35. Elias J, Boss E, Kaplan AP. Studies of the cellular infiltrate of chronic idiopathic urticaria: prominence of T-lymphocytes, monocytes and mast cells. J Allergy Clin Immunol 1986; 78: 914-8.
36. Grattan CEH, Wallington TB, Warin RP, Kennedy CTC, Bradfield JW. A serological mediator in chronic idiopathic urticaria -a clinical, immunological and histological evaluation. Br J Dermatol 1986; 114: 583-90.
37. Grattan CEH, Boon AP, Eady RAJ, Winkelmann RK. The pathology of the autologous serum skin test response in chronic urticaria resembles IgE mediated late-phase reactions. Int Arch Allergy Appl Immunol 1990; 93: 198-204.
38. Natbony SF, Philips ME, Elias JM, Godfrey HP, Kaplan AP. Histologic studies of chronic idiopathic urticaria. J Allergy Clin Immunol 1983; 71: 177-83.
39. Leznoff A, Josse RG, Denberg J, Dolovich J. Association of chronic urticaria and angioedema with thyroid autoimmunity. Arch Dermatol 1983; 119: 636-40.
40. Grattan CEH, Francis DM, Hide M, Greaves MW. Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. Clin Exp Allergy 1991; 21: 695-704.
41. Riske F, Hakimi J, Mallamaci M, et al. High affinity human IgE receptor (Fc epsilon RI). Analysis of functionaldomains of the alpha-subunit with monoclonal antibodies. J Biol Chem 1991; 266: 11245-51.
42. Hakimi J, Seals C, Kondas JA, Pettine L, Danho W, Kochan J. The alpha-subunit of the human IgE receptor (FcERI) is sufficient for high affinity IgE binding. J Biol Chem 1990; 265: 22079-81.
43. Hide M, Francis DM, Grattan CEH, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993; 328: 1599-604.
44. Fiebiger E, Maurer D, Holub H, et al. Serum IgG autoantibodies directed against the alpha chain of Fc epsilon RI: a selective marker and pathogenic factor for a distinct subset of chronic urticaria patients? J Clin Invest 1995; 96: 2606-12.
45. Ferrer M, Kinet JP, Kaplan AP. Comparative studies of functional and binding assays for IgG, anti-Fc epsilon RIalpha (alpha-subunit) in chronic urticaria. J Allergy Clin Immunol 1998; 101: 672-6.
46. Niimi N, Francis DM, Kermani F, et al. Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. J Invest Dermatol 1996; 106: 1001-6.
47. Confino-Cohen R, Aharoni D, Goldberg A, et al. Evidence for aberrant regulation of the p21Ras pathway in PBMCs of patients with chronic idiopathic urticaria. J Allergy Clin Immunol 2002; 109: 349-56.
48. National Institute of Health Consensus Development Conference Statement on Celiac Disease, 2004. Gastroenterology 2005; 128 (suppl): S1-9.
49. Farrell RJ, Kelly CP. Celiac sprue. N Engl J Med 2002; 346: 180-8.
50. Kagnoff MF. Coeliac disease: genetic immunological and environmental factors in disease pathogenesis. Scand J Gastroenterol 1985; 114(suppl): 45-54.
51. Kagnoff MF. Immunopathogenesis of celiac disease. Immunol Invest 1989; 18: 499-508.
52. Kagnoff MF. Understanding the molecular basis of celiac disease. Gut 1990; 31: 497-9.
53. Nalual AT, Nilsson S, Gudjonsdottir AH, et al. Genome-wide linkage analysis of Scandinavian affected sib-pairs supports presence of susceptibility loci for celiac disease on chromosome 5 and 11. Eur J Hum Genet 2001; 9: 938-44.
54. Broide E, Scapa E, Bloch O, et al. Evidence for aberrant regulation of MAP kinase signal transduction pathway in peripheral blood mononuclear cells in patients with active celiac disease. Dig Dis Sci 2009; 54: 1270-5.
55. Broom OJ, Widjaya B, Troelsen J, Olsen J, Nielsen OH. Mitogen activated protein kinases: a role in inflammatory bowel disease?cClin Exp Immunol 2009; 158: 272-80.
56. Roy PK, Rashid F, Bragg J, Ibdah JA. Role of the JNK signal transduction pathway in inflammatory bowel disease. World J Gastroenterol 2008; 14(2): 200-2.
57. Singh K, Deshpande P, Pryshchep S, et al. ERK-Dependent T Cell Receptor Threshold Calibration in Rheumatoid Arthritis1 J. Immunol 2009; 183; 8258-67.
58. Bonetti B, Stegagno C, Cannella B, Rizzuto N, Moretto G, Raine CS. Activation of NF-kB and c-jun Transcription Factors in Multiple Sclerosis Lesions. Implications for Oligodendrocyte Pathology. Am J Pathol 1999; 155(5): 1433-8.
59. Illei GG, Tackey E, Lapteva L, et al. Biomarkers in systemic lupus erythematosus. II. Markers of disease activity. Arthritis Rheum 2004; 50: 2048-65.
60. Hsu SD, Dickinson DP, Qin H, et al. Green tea polyphenols reduce autoimmune symptoms in a murine model for human Sjogren's syndrome and protect human salivary acinar cells from TNF-a- induced cytotoxicity. Autoimmunity 2007; 40(2): 138-47.
61. Thiel MJ, Shaefer CJ, Lesch ME, et al. Central role of the MEK/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: Potential proinflammatory mechanisms. Arthritis Rheum 2007; 56(10): 3347-57.